| 查看: 283 | 回复: 0 | |||
| 当前主题已经存档。 | |||
zlwcw木虫 (著名写手)
|
[交流]
【讨论】QIAGEN与药明康德签订分子生物标志物开发协议
|
||
|
上海——2010年1月11日——今天，QIAGEN（凯杰） 亚太区与药明康德新药开发有限公司（BVI）宣布进行合作，针对客户的需求为分子生物标志物的开发、验证及个性化医疗提供整合的解决方案，QIAGEN（凯杰）提供整套仪器设备、相关培训和耗材，而药明康德则提供实验室设施和研究人员，实施这些服务。实验室位于药明康德上海总部，并将即刻投入运行。 根据合作协议，药明康德还将协同QIAGEN（凯杰）开发生物标志物、检测试剂、个性化医疗诊断产品并推向市场。药明康德将在更广泛的范围内利用QIAGEN（凯杰）的技术，根据双方客户的需求发现和开发新药。双方还将紧密合作，不断寻求深化发展的机会。 “我们很高兴能与全球制药行业综合性研究和开发服务的领先供应商——药明康德合作，” QIAGEN（凯杰）亚太区总裁施晨阳博士说。“通过此次合作，我们创建了亚洲首家配有标准化的、整合的样本自动化制备和分析平台的实验室，为个性化医疗和其他领域进行药物发现、开发及分子诊断。我们相信此次合作为分子生物标志物检测行业提供了高品质的完整的自动化解决方案，具有里程碑意义。” “药明康德一直希望能与像QIAGEN（凯杰）这样国际一流的分子生物技术公司合作，促进我们生物标志物事业的发展，”药明康德董事长兼首席执行官李革博士说，“此次合作使我们有机会接触到创新的技术和流程，这将使我们能为客户提供更好的服务。” QIAGEN（凯杰）和新药研发 QIAGEN（凯杰）的样本制备与分析技术是全球许多领先制药公司研发实验室的重要组成部分。公司为新药研发的各个阶段提供创新技术：从最初的药物研究阶段到临床前及临床研究直至最后的新药成果产业化。通过提供以疾病和治疗方法为中心的平台，QIAGEN（凯杰）为生物医学和制药公司开发和认证新药做出了重大贡献，促进了新型分子诊断检测的发展。 宣布与药明康德的建立合作伙伴关系之前，QIAGEN（凯杰）收购了生物标志物和个性化医疗领域的DxS有限公司和SABiosciences公司，这些收购为QIAGEN（凯杰）带来了新的技术和专业应用，帮助生物医学研究人员和制药公司加速开发和认证生物标志物。最近，QIAGEN（凯杰）在中国重要的医药研发中心 —上海张江高科技园建立了新的亚洲总部，便于为其制药行业的客户提供先进的服务与支持。 关于QIAGEN（凯杰）亚洲 QIAGEN（凯杰）亚洲是公司发展最快的分公司。2005年QIAGEN（凯杰）开始在亚洲拓展业务，目前在中国、韩国、马来西亚、新加坡和印度开设10家办事处，员工达450多人。包括在日本的子公司，目前亚洲的业务量约占QIAGEN（凯杰）销售净额的13%。2006年，QIAGEN（凯杰）因公司在亚太分子检测市场中的战略举措而赢得了Frost & Sullivan颁发的竞争战略领导奖。 关于QIAGEN（凯杰） QIAGEN（凯杰） N.V.为荷兰控股公司，是全球领先的样品制备和分析技术供应商。样品制备技术用于从血液或组织等生物样品中分离和制备 DNA、RNA以及蛋白。检测技术用于鉴别这些分离所得的生物分子。QIAGEN（凯杰）已经开发并推出了500多种样品制备和分析产品并为这些实验室耗材提供自动化解决方案。公司客户遍布分子诊断实验室、学术研究机构、制药及生物技术公司和行业应用客户，产品用于法医样本鉴定、动物或食品检验以及制药过程控制。QIAGEN（凯杰）的分析技术包括全球现有的应用最广泛的分子诊断平台，该平台包括 digene HPV 检测，它被视为检测诱发宫颈癌的元凶— 高危型人乳头状瘤病毒(HPV)的“金标准，同时也包括一整套传染病检测和诊断的解决方案。QIAGEN（凯杰） 在全球30多个地方拥有3400多名员工。关于QIAGEN（凯杰）的详细信息请登录http://www.QIAGEN.com/。 关于药明康德 药明康德新药开发有限公司是全球领先的制药、生物技术以及医疗器械研发外包服务公司，在中美两国均有运营实体。作为一家以研究为首任，以客户为中心的公司，药明康德提供一系列全方位的实验室研发、研究生产服务，涉及制药和医疗器械研发的全过程。药明康德的服务旨在帮助其全球客户提高成功的机率、缩短研发周期以及降低研发成本。 网站：http://www.wuxiapptec.com 本次发布的关于QIAGEN（凯杰）的声明并非一成不变，而是具有前瞻性，包括涉及与药明康德合作的潜在结果和利益、我们的产品、市场、策略和经营成果的声明。上述声明基于我们当前的期望，涉及众多风险和不确定因素，包括与下列有关的因素，但并不仅仅限于此：市场增长和国际业务管理（包括币值波动和物流）；经营成果的易变性；市场的商业化发展（包括应用检测、临床和学术研究、蛋白质组学、女性健康/HPV检测以及分子诊断）；与客户、供应商和战略合作伙伴的关系；竞争；技术革新；需求波动；法律法规要求；识别、开发和制造与竞争者不同的综合性产品；我们产品的上市能力；以及引进技术和经营业务的融合。更多信息，请查阅SEC处QIAGEN（凯杰）的档案，包括截至2008年12月31日止我们的年度报告表20-F。本次发布的信息为截至发布日止的信息，除非法律要求，本公司不具有更新此信息的义务。 网址：http://www.wuxiapptec.com。 QIAGEN新闻稿 QIAGEN and WuXi AppTec Enter into Partnership Agreement for Molecular Biomarker Development Shanghai - January 11, 2010 - QIAGEN Asia Pacific and WuXi AppTec (BVI) Inc. today announced a partnership to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets to their respective client bases, with QIAGEN providing a complete portfolio of instrumentation, training, and consumables and WuXi AppTec providing laboratory facilities and staff to execute the services. The laboratory will be located at WuXi AppTec's campus in Shanghai and will begin operating immediately. Under the terms of the partnership agreement, WuXi AppTec will also work with QIAGEN to help develop biomarkers, assay panels, personalized healthcare diagnostics, and other products that QIAGEN intends to bring to market. WuXi AppTec will use QIAGEN's technologies for a broad range of applications in support of drug discovery and development on behalf of the company's and QIAGEN's customers. Both companies are working closely to identify additional opportunities to expand their relationship. "We are very pleased to have entered into this partnership with WuXi AppTec, a global leader in providing integrated research and development services to the pharmaceutical industry," said Dr. Victor Shi, President, Asia Pacific of QIAGEN. "In doing so, we have created what we believe to be the first laboratory of its kind in Asia equipped with a standardized, fully integrated, automated sample and assay technology platform for drug discovery, development and molecular diagnostics in personalized healthcare and other areas. We believe that this partnership is a significant milestone in providing high-quality and complete automated solutions for the molecular biomarker testing industry." "WuXi AppTec has long been interested in partnering with a premier international molecular biotechnology company like QIAGEN to support the development of our biomarker business," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "This partnership gives us access to innovative technologies and processes that will allow us to better serve our customers." QIAGEN and Drug Discovery: QIAGEN's sample and assay technologies are an integral part of research and development laboratories at many of the world's leading pharmaceutical companies. The company offers innovative technologies for each stage of drug development, from the fundamental pharmaceutical research stage via preclinical and clinical studies to the commercialization of new products. By supplying disease- and pathway-focused panels, QIAGEN contributes to the discovery and validation engines of biomedical and pharmaceutical institutions and can catalyze the development of novel molecular diagnostic assays. The announcement of the partnership with WuXi AppTec follows QIAGEN's recent acquisitions of DxS Ltd. and SABiosciences Corporation in the biomarker and personalized medicine field. These acquisitions bring additional technologies and expertise to the QIAGEN portfolio, allowing biomedical researchers and pharmaceutical companies to facilitate and accelerate the discovery and validation of biomarkers. QIAGEN also recently opened its new Asia headquarters in Shanghai's Zhangjiang High-Technology Park, a major pharmaceutical R&D hub in China, facilitating industry-leading support for its many pharmaceutical customers. About QIAGEN Asia: QIAGEN Asia is the company's fastest-growing division. QIAGEN began its strategic expansion into Asia in 2005 and currently maintains 10 Asian offices with over 450 employees in China, Korea, Malaysia, Singapore, and India. Including the subsidiary in Japan, these Asian operations currently contribute approximately 13 percent to QIAGEN's overall net sales. In 2006, QIAGEN received the Frost & Sullivan Award for Competitive Strategy Leadership in recognition of the company's strategic initiatives in the Asia Pacific molecular testing market. About QIAGEN: QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA, and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing, and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digeneHPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,400 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/. About WuXi AppTec: WuXi AppTec is a leading pharmaceutical, biotechnology, and medical-device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of laboratory and manufacturing services throughout the pharmaceutical and medical-device R&D process. WuXi AppTec's services are designed to help its global partners to improve the success, shorten the time, and reduce the cost of research and development. Web: http://www.wuxiapptec.com. SAFE HARBOR STATEMENT Statements regarding QIAGEN contained in this release that are not historical facts are forward-looking statements, including statements about the potential outcomes and benefits of the partnership with WuXi AppTec, our products, markets, strategy, and operating results. Such statements are based on current expectations that involve risks and uncertainties including, but not limited to, those associated with: management of growth and international operations (including currency fluctuations and logistics); variability of our operating results; commercial development of our markets (including applied testing, clinical and academic research, proteomics, women's health/HPV testing and molecular diagnostics); our relationships with customers, suppliers and strategic partners; competition; changes in technology; fluctuations in demand; regulatory requirements; identifying, developing and producing integrated products differentiated from our competitors' products; market acceptance of our products; and integration of acquired technologies and businesses. For further information, refer to QIAGEN's filings with the SEC, including our Annual Report on Form 20-F for the year ended December 31, 2008. Information in this release is as of the date of the release, and the company undertakes no duty to update this information unless required by law. |
回复此楼» 猜你喜欢
大家帮忙看看这个函评分数是怎样的？
已经有36人回复
-
细胞死亡新方式：铜死亡
已经有9人回复
-
药理学论文润色/翻译怎么收费?
已经有190人回复
-
安徽医科大学-药理学求博导
已经有1人回复
-
脓毒症（盲肠结扎）
已经有22人回复
-
广西医科大学基础医学院自身免疫病课题组招收基础医学、药学和生物学等专业的研究生
已经有7人回复
-
[学习资料分享] FAERS数据库的不良反应挖掘(频数法/贝叶斯法)
已经有1人回复
-
招收医学、基础医学类调剂研究生
已经有0人回复
-
是否属于脾肾阳虚证
已经有0人回复
» 本主题相关商家推荐: (我也要在这里推广)
